公开(公告)号：WO2023049727A1

公开(公告)日：2023-03-30

申请号：PCT/US2022/076753

申请日：2022-09-20

Applicant: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Inventor： STELLACCI, Francesco ,  SILVA, Paulo, Henrique, Jacob

IPC: A61K31/724 ,  A61P31/14 ,  A61P31/22 ,  C08B37/16

Abstract: The invention relates to substituted cyclodextrin (CD) compounds having C9 to C25 optionally substituted alkyl-based linker groups, which irreversibly inhibit viruses and are useful in the treatment of viral infections. While the compounds of the invention show virus inhibition in the nanomolar range they show no in-vitro toxicity in the same range of concentration.

公开(公告)号：WO2023033276A1

公开(公告)日：2023-03-09

申请号：PCT/KR2022/002845

申请日：2022-02-28

Applicant: 주식회사 레나투스

Inventor： 김희곤

IPC: C08B37/16 ,  A61K31/724 ,  A61P3/06

Abstract: 감마-사이클로덱스트린 기반 중합체를 포함하는 콜레스테롤 대사 관련 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도에 관한 것이다. 일 양상의 감마-사이클로덱스트린 중합체를 포함하는 콜레스테롤 대사 관련 질환의 예방 또는 치료용 약학적 조성물은 감마-사이클로덱스트린 기반 중합체를 포함함으로써 세포막 콜레스테롤 추출을 최소화 하여 세포독성 및 용혈활성을 일으키지 않아, 세포 내 콜레스테롤 대사 및 배출을 용이하게 하고, IL-1β, MCP-1 및 TNF-α 사이토카인 분비를 효과적으로 억제하여 우수한 항염증 효과를 나타낼 수 있다.

公开(公告)号：WO2022266039A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033347

申请日：2022-06-14

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： DOYLE, Kristian

IPC: A61P29/00 ,  A61K31/724 ,  A61P9/00 ,  A61P43/00

Abstract: The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating stroke (e.g., with anti-inflammation therapy).

公开(公告)号：WO2022197640A1

公开(公告)日：2022-09-22

申请号：PCT/US2022/020271

申请日：2022-03-14

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  AKAY, Leyla

Inventor： BLANCHARD, Joel ,  KELLIS, Manolis ,  TSAI, Li-huei ,  DAVILA VELDERRAIN, Jose ,  VON MAYDELL, Djuna ,  EFFENBERGER, Audrey ,  VICTOR, Matheus

IPC: A61K31/724 ,  A61K31/15 ,  A61K31/20 ,  A61K31/7076 ,  A61K45/06 ,  A61P25/28

Abstract: The present disclosure provides methods of inhibiting amyloid synthesis in a subject using cyclodextrin and analogs thereof. Small molecules (cyclodextrin) reverse AP0E4- associated cholesterol phenotypes and lead to significantly improved myelination both human in vitro cultures and AP0E4 targeted replacement mice. This demonstrates that AP0E4 alters cholesterol synthesis and transport in oligodendrocytes which impairs myelination. Collectively, this work uncovers a pathogenic role of AP0E4 in oligodendrocytes and myelination and enables therapeutic opportunities for Alzheimer's Disease.

公开(公告)号：WO2022165407A1

公开(公告)日：2022-08-04

申请号：PCT/US2022/014695

申请日：2022-02-01

Applicant: CLEAR SCIENTIFIC, INC.

Inventor： LI, Xinhua ,  ZAKIN, Mitchell ,  SHETTY, Chandrashekar ,  OLIVER, Piercen ,  WALLACH, Dan

IPC: A61P25/30 ,  A61P25/36 ,  A61K31/485 ,  A61K31/724 ,  A61K47/40

Abstract: Described herein are i) sequestering agents and ii) central nervous system (CNS) active agents for the treatment of intoxication due to toxic agents such as drugs of abuse, and associated symptoms. Also disclosed herein, are a cucurbituril and naloxone for use in the treatment of opioid overdoses through sequestering and excretion of the bound molecule of interest through the urine. Also provided herein, are kits and methods of treatment of the disclosure.

公开(公告)号：WO2022148456A1

公开(公告)日：2022-07-14

申请号：PCT/CN2022/070958

申请日：2022-01-10

Applicant: QUADRIGA BIOSCIENCES, INC.

Inventor： JANDELEIT, Bernd ,  TAM, Peter ,  LIU, Ruifang ,  YAN, Shixiang

IPC: A61K31/197 ,  A61K31/724 ,  C07C229/34 ,  C07C215/68 ,  C07C229/22 ,  C07C229/42 ,  C07C229/60 ,  C07D303/46 ,  A61K47/40 ,  A61K9/00 ,  A61P35/00

Abstract: Pharmaceutical compositions comprising a chemotherapeutic agent based on a β-substituted β-amino acid derivative are disclosed. The pharmaceutical compositions include a β-substituted β-amino acid derivative and a cyclodextrin derivative. The pharmaceutical compositions are useful for treating cancer.

公开(公告)号：WO2022109052A1

公开(公告)日：2022-05-27

申请号：PCT/US2021/059763

申请日：2021-11-17

Applicant: BEXSON BIOMEDICAL, INC.

Inventor： BECKER, Jeffrey ,  PETERSON, Gregg

IPC: A61K31/5513 ,  A61K31/5517 ,  A61K31/724 ,  A61K45/06 ,  A61P25/00

Abstract: Provided herein are subcutaneous formulations of flumazenil that are useful for treating a variety of disease and disorders. The subcutaneous flumazenil formulations provided herein reduce injection site irritation and pain and allow for home administration to enhance patient compliance.

公开(公告)号：WO2022047241A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/048072

申请日：2021-08-27

Applicant: BEREN THERAPEUTICS P.B.C.

Inventor： KERWIN, Diana ,  CAMM, Jason

IPC: A61K31/724 ,  A61K9/08 ,  A61K9/10 ,  A61P3/06 ,  A61P9/10

Abstract: Disclosed herein are methods for reducing an amount of and/or a size of, and/or changing the shape of circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of treating cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.

公开(公告)号：WO2022040580A1

公开(公告)日：2022-02-24

申请号：PCT/US2021/046984

申请日：2021-08-20

Applicant: RESOLUTE SCIENCE

Inventor： BARNETT, Faith

IPC: A61K31/721 ,  A61K31/724 ,  A61K47/69 ,  A61K47/50 ,  G01N33/58 ,  G01N33/60

Abstract: The present invention relates to compounds that target monocytes, macrophages and other cells (such as dendritic cells) that express CD-206, particularly those cells at are assembled at a site of disease, using a target moiety coupled to a glucan backbone. The compounds disclosed here preferably comprise a glucan backbone, a targeting moiety, a targeting moiety linker, a payload and optionally a payload linker. The present invention also provides methods of making such compounds and compositions. The present invention also provides diagnostic methods and methods of treatment using compounds comprising a target moiety coupled to a glucan backbone.

公开(公告)号：WO2022039206A1

公开(公告)日：2022-02-24

申请号：PCT/JP2021/030275

申请日：2021-08-19

Applicant: 国立大学法人　東京医科歯科大学 ,  国立大学法人東海国立大学機構

Inventor： 伊藤　美智子 ,  田村　篤志 ,  由井　伸彦 ,  菅波　孝祥

IPC: A61K31/724 ,  A61K47/60 ,  A61P1/16 ,  C08L71/02

Abstract: 本発明は、非アルコール性脂肪肝炎の治療に用いるための組成物および治療方法を提供することを課題の一つとし、その解決手段の一つとして、複数の環状分子と、末端基を有する直鎖状分子とを含む、酸分解性のポリロタキサン化合物を含む、非アルコール性脂肪肝炎の治療に用いるための組成物を提供する。本発明において用いられるポリロタキサン化合物は、細胞内の酸性環境下またはｐＨ４．０～６．０の酸性環境下で分解するものでありうる。また、ポリロタキサンの環状分子はβ－シクロデキストリンであることができ、β－シクロデキストリンの水酸基が水溶性官能基で修飾されていてもよい。